Bioasis Technologies

Bioasis Technologies FCF/Debt

The Free Cash Flow to Debt Ratio of Bioasis Technologies (BIOAF) as of Oct 29, 2026 is -191.16 %. In the previous year, Free Cash Flow to Debt Ratio was 1,560.35 % — a change of -112.25% (lower).

FCF/Debt

-191.16 %

YoY

-112.25%

Last updated:

Free Cash Flow to Debt Ratio of Bioasis Technologies is 2022 -191.16 % . Free Cash Flow to Debt Ratio of Bioasis Technologies was 2021 1,560.35 % . It decreases by -112.25% lower compared to the previous year.

The Bioasis Technologies FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2016
-477.06 CAD
Jan 1, 2017
-7,504.23 CAD
Jan 1, 2020
-328.70 CAD
Jan 1, 2021
1,560.35 CAD
Jan 1, 2022
-191.16 CAD
The Bioasis Technologies FCF/Debt history
YEARFCF/DebtYoY
-191.16 %-112.25%
1,560.35 %-574.70%
-328.70 %-95.62%
-7,504.23 %+1,473.01%
-477.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

Free Cash Flow to Debt Ratio of Bioasis Technologies is -191.16 % in 2022.

Free Cash Flow to Debt Ratio of Bioasis Technologies changed from 1,560.35 % to -191.16 %, representing a -112.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bioasis Technologies

All Key Metrics — Bioasis Technologies